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Introduction 
 
Pulmonary aspergillosis is one of the most severe human diseases caused by fungi threatening 
especially immunodeficient patients. This expanding population is composed of patients with 
advanced HIV infection, prolonged neutropenia, and inherited immunodeficiency and patients 
who have undergone lung transplantation and allogeneic hematopoietic stem cell 
transplantation. The most severe form of pulmonary aspergillosis is invasive pulmonary 
aspergillosis, which leads to high mortality. In this disease the hyphae grow in the lung tissue, 
invading the blood vessels they can spread hematogenously to other organs causing fungal 
sepsis and death. For the treatment various antifungal drugs are used, from which the azoles 
are the most important (itraconazole, posaconazole, voriconazole). The mortality is also high 
in the treated patients, the cause of this can be the developing resistance of the fungi against 
the antifungal agents, which is increasing according to studies. In the case of azole resistance 
the fungi will be often resistant of more azoles simultaneously. Since the azoles are the most 
important drugs for treating aspergillosis, the spread of resistance against them is a serious 
problem during the treatment of immunocompromised patients. Therefore is an urgent task 
developing and introducing new antifungal drugs to human therapy. The antifungal protein 
produced by Penicillium chrysogenum (PAF) is a promising drug candidate. This protein was 
previously shown to be fungicide in vitro for some pathogenic fungi (Aspergillus and diverse 
dermatophytons), without toxic effects on mammalian cells. 
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Aims 
 
We started to research the antifungal protein produced by Penicillium chrysogenum (PAF) 
due to the spread of the azole resistance among the Aspergillus species, to create a new 
antifungal drug which is effective against Aspergillus species. Since the protein had been 
examined in vitro in the aspect of toxicology and mycology, our aim was to explore the in 
vivo effects of PAF:  
1. Examination of the potential toxic and proinflammatory effects of PAF in animal 
model by local and systemic administration.  
2. Verification of the presence and function of PAF in the tissues of the treated animals. 
3. Creating a stable animal model of invasive pulmonary aspergillosis. 
4. Demonstration of the effectiveness of PAF in invasive pulmonary aspergillosis animal 
model with intranasal and intraperitoneal administration.  
5. Verification of the advantages of coadministration of PAF and amphotericin B (AMB) 
in invasive pulmonary aspergillosis animal model. 
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Materials and methods 
Purification of PAF 
Purification of PAF was carried out as described previously. Briefly, P. chrysogenum NCAIM 
00237 was grown in a sucrose (20 g·l−1)–NaNO3 (3 g·l−1) minimal medium for 72 h at 25 °C 
with shaking. Mycelia were removed with centrifugation and the low molecular weight 
protein fraction of the supernatant was separated in Amicon Stirred Cells (Millipore, Billerica, 
MA, USA). PAF was purified with ion exchange chromatography on a CM Sephadex Fast 
Flow column (Amersham-Pharmacia, Uppsala, Sweden). The purity of the protein was tested 
on SDS-PAGE and by Western blotting. PAF was dissolved in physiological saline for the in 
vivo experiments. 
 
Animal care 
Animal experiments conformed with the guidelines of the European Community 
(86/609/EEC). The experimental protocol was approved by the institutional Animal Care 
Committee of the University of Debrecen. The mice were housed in plastic cages with mesh 
covers, and fed with pelleted mouse chowand water ad libitum. Room illumination was an 
automated cycle of 12 h light and 12 h dark, and room temperature was maintained within the 
range of 22–25 °C. Mice infected with A. fumigatus were kept in isolation cages with high-
efficiency particulate air filters. These cages were continuously ventilated, and slightly 
negative air pressure was used to prevent infection from fungal spores. Each cage was 
inspected at least three times daily. 
 
Administration of PAF 
12 week old C57/Bl6 mice of both sexes were used in all in vivo experiments. First the mice 
were randomized into six groups (a control group and mice treated with 5, 25, 125, 250 and 
2700 µg·kg−1 PAF dissolved in sterile physiological (0.9%) saline; 
10 animals per group) for the long time experiment and into two groups (control group and 
mice treated with 2700 µg·kg−1 PAF; 5 animals per group) for the short time experiment. In 
the latter case the animals were treated daily for 2 weeks. To investigate the long term effect 
of PAF mice were treated once a week for 8 weeks. In this case we wanted to know if PAF 
provokes an immune response when applied for a longer period. Since PAF inhibited the 
growth of A. fumigatus by 95% in 125 µg·kg−1 concentration, we applied it in a number of 
higher concentrations. Mice were slightly anesthetized with pentobarbital (50 mg·kg−1) 
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intraperitoneally then the above solutions were administrated by pipettes into the nose of the 
animals in a 50 µl final volume. Under these conditions the solution reaches the lungs through 
normal breathing. The efficiency of the procedure was tested by applying a dye solution. The 
animals in the control groups were treated with 50 µl drug free physiological saline always. 
The weight of the mice wasmeasured on the first and the last days of the short term 
application and once a week in the long term application. 
 
Histological examination and lung injury score 
To explore the possible side effects of short and long term application of PAF, the lungs, the 
kidneys, and the liver of the animals were examined histologically from control group and 
group treated with the highest (2700 g·kg−1) dose of PAF. The animals were killed on the last 
day of PAF treatment (14th or 56th day). The weight of the removed organs was measured. 
Then tissue samples were fixed in 8% buffered formalin (24 h) andembedded in paraffinwax 
(Shandon Pathcenter, Thermo-Shandon, USA). 4 µm sections were cut and Hematoxylin-
eosin (H&E) staining was performed. The samples were investigated with a LEICA DM 2500 
microscope equipped with a LEICA DFC 420 camera (Leica Microsystems, Germany) and 
the images were acquired using LEICA Application Suite (LAS) V3 software. The alveolar 
exudates/edema and hemorrhage were scored on a scale of 0–3 (0, absent; 1, mild; 2, 
moderate; 3, severe) from five randomly chosen fields in each sample. 
 
Blood collection and cell counting 
Blood samples were taken at the beginning and at the end of the two week long experiment 
from control group (n = 16) and group treated with the highest (2700 µg·kg−1) dose of PAF (n 
= 10). Mice were slightly anesthetized with pentobarbital and 200 µl blood was collected into 
a cup containing 40 µL acid citrate dextrose (ACD, Vacutainer tube, Becton Dickinson 
Diagnostics-Preanalytical Systems Plymouth, UK) by puncture of the retrobulbar venous 
plexus with a 1.5 mm diameter glass capillary. ACD anticoagulated whole blood was 
analyzed by Siemens Advia-120 hematology analyzer with Multi Species software (Deerfield, 
IL, USA), counting the number of the white blood cells and the neutrophil granulocytes. In 
addition, the level of liver enzymes and the ions in the plasma were measured to explore the 
possible toxic effects of PAF by Roche Integra 800 (Roche Diagnostics Mannheim, 
Germany). 
 
 7 
 
Sample preparation for mass spectrometry and determination of relative PAF amounts in lung 
samples 
PAF treated (2700 µg·kg−1, n = 5) and control (n=4) animals were sacrificed and lungs were 
removed 4 h after the nasal administration of the solutions. The lungswere immediately frozen 
in liquid nitrogen and kept on−70 °C until analysis. The frozen lung tissue was homogenized 
and the proteins from the homogenate were acetone precipitated and re-dissolved in 25 mM 
ammonium bicarbonate. For protein concentration measurement the Bradford method was 
utilized. For trypsin digestion 100 µl sample and 0.25 ng trypsin was used at 37 °C overnight 
and 10 µg protein was used for each mass spectrometry analysis. 
Multiple reaction monitoring (MRM/SRM) based mass spectrometry method was developed 
for PAF measurement. The 1041.4/1038.6 and 1249.1/1245.9 PAF specific transitions were 
used. The MRM scans were performed on a 4000 QTRAP (ABSciex, Farmingham, USA) 
mass spectrometer using NanoSpray II MicroIon Source and controlled by the Analyst 1.4.2 
software (ABSciex). The liquid chromatography was done on an EasynLC II nano HPLC 
(Bruker, Bremen, Germany) and the peptide mixture was separated on Zorbax 300SB-C18 
column (Agilent, Santa Clara, USA) using a 30 min acetonitrile/water gradient at a flow rate 
or 300 nl·min−1. Specificity of the MRM/SRM transitions was tested by analyzing mouse lung 
tissue samples and their combination with 250 fmol PAF. For the estimation of PAF 
concentration the area under the curve (AUC) of the acquired spectra was calculated. The 
AUC were normalized to the protein content of the given lungs in each case. Those MRM 
spectra were used for AUC calculationswhere the intensity of the signal exceeded 150 cps 
(count per second) in both MRM transitions. 
 
In vitro test of antifungal activity of PAF in the lung 
Antifungal activity of PAF was tested using isolated lung tissue (n = 3). Lungs were removed 
6 h after administration of 2700 µg·kg−1 PAF, homogenized with quartz sand in 900 µl 
physiological saline and centrifuged at 4 °C, 16,100 g for 10 min. The antifungal activity of 
the supernatant was determined on A. nidulans with micro-titer plate assay as described 
previously. Briefly, 103 conidia of A. nidulans spore suspension in 100 µl YPD liquid (1% 
yeast extract, 2% peptone, 2% glucose, pH 7.0) was incubated with 50–75–100 µl lung tissue 
homogenization overnight at 37 °C in a micro-titer plate. The growth of A. nidulans was 
determined according to optical density at 630 nm. The antifungal activity of lung tissue from 
mice treated with PAF free physiological saline (n = 3) was also determined as control. 
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Model of LPS-induced acute lung inflammation 
For induction of acute lung inflammation, C57/Bl6 mice were divided into 3 groups, slightly 
anesthetized with pentobarbital and physiological saline (n = 4), PAF (2700 µg·kg−1; n = 4), 
or lipopolysaccharide (LPS, Escherichia coli serotype 055:B5; Sigma-Aldrich; 250 µg·kg−1; n 
= 6) was instilled intratracheally in a total volume of 50 µl physiological saline. This dose was 
based on previous studies. The treatment was not lethal, the animals recovered quickly from 
the procedure. 
 
Measurement of pulmonary edema 
To determine the pulmonary edema in acute lung inflammation, C57/Bl6 mice were divided 
into 3 groups. After a slight anesthetization with pentobarbital, physiological saline (n = 4), 
PAF (2700 µg·kg−1; n = 4), or lipopolysaccharide 
(LPS, 250 µg·kg−1; n = 4) was instilled intratracheally in a total volume of 50 µl physiological 
saline. 24 h after the treatment the lungs were removed and the wet weights were measured. 
Lung tissues were weighed again after 3 days drying at 60 °C. The wet-to-dry ratio was 
calculated as follows: wet-to-dry ratio = (wet weight – dry weight) / dry weight. 
 
Positron emission tomography (PET) 
The glucose analog 18FDG (2-[18 F]fluoro-2-deoxy-D-glucose) was synthesized and labeled 
with the positron-decaying isotope 18F according to a previously described method. Images 
were collected using the MiniPET-II system, a dedicated small animal PET scanner. FDG-
PET experiments were carried out on mice randomized into three groups (control, n = 4; PAF, 
n = 4; LPS, n = 6) on the next day of the intranasal application of solution. The animals were 
fasted for a minimum of 6 h before undergoing PET. After an injection of 4–6 mBq of 18FDG 
in 150 µl of phosphate buffered saline (PBS) via the tail vein, a dynamic PET scan was 
acquired using the small animal PET camera. Mice were maintained under isoflurane 
anesthesia during the injection and scanning periods. They were kept warm while under 
anesthesia to maintain a body temperature of 35 °C. Three-dimensional regions of interest 
(ROI) were manually drawn around the edge of the lung activity by visual inspection using 
BrainCad software. The standardized uptake value (SUV) was calculated by multiplying the 
mean concentration activity in the ROI with mouse weight and dividing by injected dose. 
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Irritant dermatitis 
The irritant dermatitis was evoked as described previously with minor modifications. Namely, 
stock solutions of PAF and phorbol-12-myristate-13-acetate (PMA) were prepared in 
physiological saline and DMSO, respectively and then both compounds were further diluted 
in hydrophilic cream (Unguentum hydrophylicumnon-ionicum, Pharmacopoeia Hungarica 
VIII). Animals, 12 female C57/BL6 mice, were randomized into three groups (control, PMA, 
and PAF) and the thickness of their ears was measured. Mice were treated by smearing 4 × 10 
µL of vehicle (physiological saline), PMA (500 µg/ml), or PAF (100 µg/ml) onto the inner 
and outer surface of both ears. After 24 h, thickness of the ears was measured in vivo again. 
Finally the mice were sacrificed and tissue samples were taken for histology. 
 
In vitro study assay 
Minimum inhibitory concentration (MIC) determination of AMB and PAF and the drug 
combination studies were performed according to CLSI M38-A2 guidelines. The final 
concentrations of the tested drugs ranged from 0.0625 to 16 µg/mL for AMB, and from 25 to 
500 µg/mL for PAF. The MICs of the antifungal agents were determined after 48 h of 
incubation at 35 °C as the lowest drug concentration at which there was complete inhibition 
of growth. In a checkerboard assay, combinations of the two drugs were determined according 
to the MIC values of the drugs used alone. The interaction of AMB and PAF was assessed by 
calculating the fractional inhibitory concentration index (FICI) with the following formula: 
FICI=((MIC A in combination)/MIC A)+((MIC B in combination)/MIC B). The interaction is 
synergic if the FICI is ⩽0.5; indifferent if the FICI is >0.5 and ⩽4; and antagonistic if the 
FICI is >4. 
 
Preparation of fungal conidia 
Inocula of A. fumigatus AF293 (clinical isolate from human lung tissue) were prepared by 
culturing the test organisms on minimal nitrate medium. Freshly grown (6 days) conidia were 
harvested in PBS-0.01% Tween 80 and counted in a Bürker chamber. 
 
Infection of mice with A. fumigatus Q1 
Mice were immunosuppressed with 250 mg/kg cyclophosphamide (Endoxan, Baxter, IL, 
USA) intraperitoneally (IP) three days before and one day after infection with A. fumigatus 
conidia. A total of 3.5 × 106 conidia dissolved in 50 µL PBS was given to mice intranasally 
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under anesthesia with isoflurane. The number of conidia was chosen to produce 100% 
mortality. This was tested in preliminary experiments. Gentamicin was added to the water of 
the mice (5mg/kg). The survival of the animals was monitored three times daily after 
infection. All infected animals were humanely terminated if they presented severely reduced 
mobility (i.e., unable to reach their water or food) or substantial distress. After the death of 
animals, their organs were removed and histological examination was carried out. 
 
Intranasal PAF treatment of animals suffering from invasive pulmonary aspergillosis 
In five independent experiments, immunosuppressed mice were randomly divided into three 
groups from which two were Aspergillus conidia infected. Among the infected groups the 
first group was treated with 5.4 mg/kg PAF (26 mice), the second group with PAF-free PBS 
(positive control, 23 mice) intranasally in the final volume of 50 µL. The intranasal 
application of PAF was described earlier. Briefly, mice were slightly anesthetized with 
isoflurane, then 2.7mg/kg PAF dissolved in PBS were administered by pipette into the nose of 
the animals in a 50 µL final volume. Under these conditions the solution reaches the lungs 
through normal breathing. Treatments lasted until the death of animals from the day of the 
infection twice a day (morning and afternoon). The control group (negative control, six mice) 
was not infected but immunosuppressed and treated intranasally with PAF-free PBS twice a 
day. Some animals from the infected group were killed 3 days after the infection, and their 
organs were examined histologically. 
 
Intraperitoneal PAF treatment of healthy animals 
Mice were randomly divided into two groups. The first group (n=8) was treated IP with 5.4 
mg/kg PAF dissolved in 100 µL PBS twice a day and intranasally twice a day with 2.7 mg/kg 
PAF dissolved in 50 µL PBS for 7 days. The second (control) group (n=8) was treated with 
PAF-free PBS in the same way. On the eighth day, some animals were killed and the organs 
were removed for histological examination. On the first and last days of the experiment, body 
weight was measured, blood was collected, and blood cell count and other plasma parameters 
were determined. 
 
Combined treatment with PAF and amphotericin B of animals suffering from invasive 
pulmonary aspergillosis 
In two independent experiments, immunosuppressed mice were randomly divided into five 
groups (all together 11 mice per group). Animals in four groups were Aspergillus conidia 
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infected, the non-infected group was the negative control. All antifungal treatment started on 
the day of the fungal infection and lasted till the death of the animals. The first infected group 
was treated with PAF and amphotericin B-desoxycholate (Fungizone, Bristol-Myers Squibb, 
Montreal, QC, Canada), the second group with PAF, the third group with AMB and the 
positive control group only with PBS. A total of 5.4 mg/kg PAF dissolved in PBS was 
injected IP twice a day in 100 µL final volume, and 50 µL were administered by pipette into 
the nostrils of the animals under anesthesia once a day. One hundred microliters AMB were 
injected IP in 5 mg/kg concentration three times as follows: 1, 2 and 4 days after the fungal 
infection. The animals in the negative control group were treated only with PBS in the same 
way as the PAF treated group. After the death of the infected animals, their organs were 
removed for histological examination. 
 
Chemicals and statistical analysis 
Chemicals, unless otherwise stated, were purchased from Sigma (St. Louis, USA) and were of 
analytical grade. Averages were expressed as the means±standard error (SE) of the mean. The 
differences between control and treated animals were assessed using one-way analysis of 
variance (ANOVA) and all pairwise multiple comparison procedures (Student–Newman–
Keuls method). The F test was used to test significance, and a P value of <0.05 was 
considered statistically significant. Percentage survival was computed with the Kaplan–Meier 
method. The mortality rate as a function of time was fitted to a Gompertz mortality rate 
equation. The equation is as follows: Rm = (R0 – pl) x exp(α • t), 
where R0 is the initial mortality rate, pl is plateau at the end of experiment, α is the Gompertz 
parameter and t is the time. The significance of differences between survival curves was 
assessed as the statistically accepted differences in the fitted Gompertz parameter (α) and with 
the log-rank (Mantel–Cox) test. The results were evaluated with GraphPad Prism 6.0 software 
(La Jolla, CA, USA). 
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Results 
 
Histological examination and laboratory values of intranasally PAF treated animals 
PAF was tested in vivo in several doses (5–2700 µg·kg−1) either for a prolonged (8 weeks) or 
for a short period (2 weeks) in a high concentration (2700 µg·kg−1) on mice. In case of the 
latter PAF was applied daily while in case of the former it was administered once a week. 
Since the most probable application of PAF in human therapy would be to treat aspergillosis 
which would require the drug to be introduced via the airways, presumably using inhalators, 
we attempted to simulate this condition by introducing PAF to mice via the airways. The drug 
was thus introduced after anesthesia through the nose while the applicability of the method, 
that is whether the liquid thus applied actually reached the alveoli, was confirmed in 
independent experiments. During the course of the experiments none of the animals died due 
to the drug application. Furthermore, the weight and physical activity of the animals remained 
unchanged during the study period. To test for possible morphological alterations due to the 
application of PAF, histological examination of the lungs, kidney, and liver of the animals 
was carried out. We did not observe any signs of pathological alterations in the lungs, in the 
kidney, and in the liver following the short (2 weeks, daily) application of the protein. Similar 
observations were made after the long (8 weeks, once a week) treatment, too. Both the total 
white blood cell count (1.94 ± 0.15 and 1.83 ± 0.18 109 L−1; control vs. treated, respectively; 
F(1,8) = 0.2, p = 0.66) and the percentage of neutrophils (2.08 ± 0.57 and 2.10 ± 0.29%; control 
vs. treated, respectively; F(1,8) = 0.001, p = 0.98) remained unchanged in the highest dose 
(2700 µg·kg−1) of PAF used daily for 2 weeks. Furthermore, the concentration of liver 
enzymes and ions in the blood did not show a significant elevation/alteration after PAF 
treatment. There was no significant change in the weight of the animals during the application 
of PAF. The average weight of the animals in the short term application of PAF was 21.6 ± 
0.2 g at the beginning and 21.7 ± 0.3 g at the end (F(1,8) = 0.01, p = 0.92), and 20.7 ± 0.8 g and 
20.4 ± 0.2 g in the control group (F(1,8) = 0.17, p = 0.70). The PAF treatment did not alter the 
growth of the animals in the long term (8 weeks) experiment. These results clearly established 
that the application of PAF neither induced any gross changes in organmorphology nor 
initiated an overall immune response in the animals. 
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Presence and activity of PAF in the lungs 
To prove the efficiency of our method – that is to clearly establish that not only the solvent 
but also PAF was indeed present in the lungs following intranasal application – mass 
spectrometry was used to determine the presence of PAF in the lungs of PAF treated mice. 
The amount of PAF was calculated as the area under the curves of the mass spectrometry 
graphs. The relative amount (normalized to total protein content) of PAF was measured in 
control (n = 4) and PAF treated (n = 5) lung samples. The results demonstrate that the 
antifungal protein is clearly present in the lungs of PAF treated animals and its amount (3.2 ± 
0.7 AUC·mg−1 protein) is significantly different from zero (F(1,18) = 22.121, p = 2.1·10−3) 
and even significantly greater than that in the standard (1.4 ±0.7 AUC·mg−1 protein, F(1,12) = 
6.8, p = 0.023). Note also that the values obtained for PAF content from untreated mice were 
not significantly different from zero (0.010 ±0.007 AUC·mg−1 protein; F(1,14) = 0.197, p = 
0.665). To prove that PAF retained its antifungal activity in the lungs, homogenates of control 
and PAF treated mice lung were used in in vitro tests against A. nidulans. 100 µl of the 
supernatant of such homogenates inhibited the growth of A. nidulans approximately as a 50 
µg·ml−1 PAF solution did. Namely, it reduced significantly the growth of A. nidulans to 25.2 
± 1.6% (F(1,4) = 3350.5, p = 5.3·10−7; with 100% being the growth in culturing medium). 
Decreasing the amount of supernatant used in 75 µl or 50 µl resulted in increasingly smaller 
39.4 ± 1.2% (F(1,4) = 3524.1, p = 4.8·10−7) and 55.3 ± 1.5% (F(1,4) = 1184.5, p = 4.3·10−6) but 
still significantly decreased growth, respectively. Lung tissue from untreated mice did not 
show any growth inhibitory effect on A. nidulans (93.1 ± 0.6%). 
 
Inflammatory response in the lungs following PAF application 
To test whether PAF application would induce inflammation of the lungs a novel non-
invasive method based on 18FDG positron emission tomography was developed. The method 
is sensitive to all cellular processes that metabolize glucose since 18-flurodeoxyglucose is 
taken up by glucose transporters into the cells and cannot bemetabolized after its 
phosphorylation to 18FDG-6-phosphate. Its accumulation is, therefore, is proportional to the 
glucose uptake and, consequently, to the metabolic activity of the cell. FDG-PET experiments 
were carried out on 14 mice randomized into 3 groups. The 3D image of the body was 
reconstructed from the acquired images and the lungs were identified as Regions of Interest 
(ROI). The intensity of 18FDG accumulation within the ROI was assessed as a measure of 
inflammation. This method enabled us to give an estimate of and to follow any occurring 
inflammatory reactions in individual mice. 
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Mice were treated on the previous day with physiological saline, saline containing PAF (2700 
µg·kg−1) or saline containing LPS (250 µg·kg−1) as positive control. It is clearly visible from 
the images that while PAF itself did not increase the emission intensity in the lungs as 
compared with control, LPS caused a marked elevation in the emission, indicating the 
presence of inflammation. These observations were quantified by calculating the emissions in 
the ROI. Pooled data showed a significant decrease in the PAF treated group (0.50 ± 0.01 
SUV, n = 4, F(1,6) = 33.43, p = 0.01) as compared with the control (0.72 ± 0.04 SUV, n = 4) 
and a significant elevation in the LPS treated animals (0.99 ± 0.09 SUV, n = 6, F(1,8) = 5.55, p 
= 0.04). To validate the PET results, we sacrificed some animals from each group and 
conducted histological examination. H&E staining of the sections confirmed the absence of 
any inflammation in the control and the PAF-treated, while the presence of extensive 
inflammation in the LPS-treated animals. In addition the lung injury score was significantly 
higher in the LPS treated group (3.7 ± 0.5, F(1,11) = 19.5, p = 0.001) than in the control group 
(1.0 ± 0.4). On the other hand the score of PAF treated group (1.3 ± 0.3, F(1,11) = 0.39, p = 
0.54) was almost identical to that of the control animals. Furthermore, unlike for LPS, PAF 
treatment was not accompanied by the development of pulmonary edema. In the simple assay 
for lung inflammation and pulmonary edema formation, LPS showed significantly increased 
lung wet-to-dry weight (4.04 ±0.10, F(1,6) = 11.041, p = 0.016) as compared with the control 
(3.61 ± 0.07), while PAF did not elevate this ratio significantly (3.81 ± 0.10, F(1,6) = 2.75, p = 
0.15) when examined 24 h after the treatment. 
 
Inflammatory response of the skin following PAF application 
Through the human application of PAF against aspergillosis would most likely be through 
inhalation, its surface application might also be considered, since PAF has inhibitory effects 
on several dermatophytes. To test for the possibility that PAF could induce local, contact 
inflammation on the skin, a contact dermatitis model was used where the swelling of the ears 
was measured. PAF treatment did not cause the swelling of the ears in the dose used. On the 
other hand, PMA, used as a positive control, induced a clear edema, indicating inflammation. 
This latter observation underlined that the model was sensitive enough to detect any 
inflammation. In particular, the increase in the thickness of ears of mice in the PMA group 
(57.5 ± 29.2 µm; n = 4) was significantly greater (F(1,10) = 5.42, p = 0.04) due to edema 
formation as compared to their control counterparts. In contrast, the increase in the thickness 
of the ears of PAF treated animals was essentially identical to that in the control group (22.5 ± 
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5.0 and 23.8 ± 9.2 µm; in the control and in the PAF treated group, respectively, n = 4 for 
both groups, F(1,10) = 0.06, p = 0.81). 
 
Effects of intraperitoneal application of PAF on healthy animals 
As the nasal application of  PAF was not as successful as expected, the drug was administered 
IP as well. Control non-fungal-infected mice were treated IP with 0 and 5.4 mg/kg doses of 
PAF twice a day for 1 week. Blood samples were collected at the beginning and end of the 
experiment. Although the total white blood cell count decreased slightly (F (1,14)=35.5, 
P=3×10−5), the percentage of neutrophils remained unchanged (F(1,14)=0.71, P=0.41). 
Furthermore, the concentration of liver enzymes and ions in the blood did not show 
significant (0.01<F(1,14)<4.39, 0.08<P<0.93) elevation/alteration after PAF treatment. There 
was no significant change in the weight of the animals during the application of PAF. The 
average weight of the animals was 17±0.3 g at the beginning and 17.2±0.4 g at the end 
(F(1,14)=0.19, P=0.67). These results suggest that the intraperitoneal application of PAF neither 
induced any overall changes in the animals nor initiated an overall immune response, 
similarly to the nasal application. 
 
Survival and histological examination of animals suffering from pulmonary aspergillosis 
treated intranasally with PAF 
As the most likely application of PAF in human therapy is expected to be the treatment of 
lung aspergillosis, which implies the administration of the drug via the airways, we simulated 
this procedure by introducing PAF intranasally to mice at a high concentration (5.4mg/kg). 
Infected animals suffering from IPA were evidently sick, moved slowly and their fur was 
matted. Moreover, their weight decreased significantly. PAF delayed the death of animals by 
~ 1 day, but all animals had died by day nine. Log-rank analysis showed no significant 
differences (P=0.86) between the survival curves. In contrast with this, all of the control non-
infected mice, treated only with PAF in PBS, showed 100% survival and their body weight 
was stable. Overall, intranasal PAF treatment did not increase significantly (F(1,47)=0.23, 
P=0.63) the average survival of the animals. Histological examination of the lungs displayed 
severe pulmonary lesions characterized by multifocal to coalescent infiltrations of 
macrophages and neutrophils associated with vascular phenomena (thrombi, necrosis and 
hemorrhages) and alveolar and bronchiolar epithelial cell necrosis. There were no remarkably 
positive effects in the lungs following intranasal application of the antifungal protein. In 
positive control mice, a high number of proliferating hyphae and coagulation necrosis were 
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observed in the blood vessels, septa, bronchioles and alveoli. In the lungs from mice treated 
intranasally with PAF, hyphae were also frequently observed in the bronchioles and the 
alveoli. However, invasion of hyphae into blood vessels was not observed. The lung injury 
score was significantly higher in both cases (6±0 and 5.3±1.2 in positive control and PAF-
treated mice, respectively) than in uninfected negative control animals (0.3±0.3; F(2,6)=18.5, 
P=0.003). The PAF-treated animals had values slightly but not significantly lower than the 
untreated ones (F(1,4)=0.31, P=0.61). It is important to mention, however, that we did not find 
fungal infection in the kidneys or in the liver. 
 
Combined treatment of animals suffering from pulmonary aspergillosis 
To increase the positive effects of PAF, its intranasal application was complemented with 
intraperitoneal injection. The combined application of PAF and AMB was also tested. Before 
the in vivo application, an in vitro drug combination assay of AMB plus PAF was performed. 
With AMB and PAF alone, the MIC values against A. fumigatus AF293 proved to be 1 and 
300 µg/mL, respectively. FICI values indicated an in vitro synergic effect when AMB was 
combined with PAF. The FICI value calculated from the individual and combined MICs (0.25 
µg/mL of AMB and 50 µg/mL of PAF) of the drugs is 0.42. Infected mice were treated with 
PAF, amphotericin B (5 mg/kg), and both antifungal drugs concomitantly. It is clearly visible 
that although neither PAF nor AMB alone increased survival, the combined application 
resulted in a remarkable extension of life expectancy. In this experiment, all infected animals 
died within 7 days independently of the treatment they received. In the untreated infected 
group, more than 80% of the animals died after 5 days. Importantly, on this day more than 
50% of the PAF or AMBtreated animals were still alive. It is noteworthy that in the group 
receiving the combined treatment, only 30% of the animals died by the 5th day. After 6 days, 
all PAF-treated animals died, meanwhile 9% of the AMB-treated animals and 27% of the 
combined treatment animals were alive. Summing up, individual PAF or AMB treatment 
extended the survival of the animals by 1 day, and some animals in the combined treatment 
group lived 2 days longer than those in the untreated group. To test the differences between 
the survival curves, Equation (1) was fitted to the data points. Although the Gompertz 
mortality rate was high (α=1.596) in the positive control group, it was significantly lower in 
the PAF (α=0.6882, P<0.001) and AMB (α=0.6146, P<0.001) treated groups. Furthermore, 
the combined treatment significantly slowed down the mortality (α=0.4831, P<0.001) when 
compared with the untreated group. As all animals died in all groups, the plateaus of the 
curves were assumed to be zero. The log-rank test also proved that the survival curves of the 
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treated groups are significantly different from that of the untreated one (P=0.04). There was 
no significant difference in the average survival time between the single treatment groups 
(F(1,20)=0.20, P=0.66). PAF treatment alone caused a close to significant increase (F(1,20)=4.02, 
P=0.06) in the average survival of the animals. However, AMB alone (F(1,20)=4.88, P=0.04) 
and the combined PAF and AMB treatment (F(1,20)=6.99, P=0.02) increased significantly the 
lifetime of the animals. These observations were validated by histological examination. In the 
lungs from IP PAF-treated mice, a number of proliferating hyphae and coagulation necrosis 
were noted in bronchioles and alveoli. In the lungs from mice treated with PAF and AMB, 
hyphae were not observed. H&E staining of sections confirmed less extensive inflammation 
in the combined AMB and PAF-treated animals. In addition, PAS staining proved the 
manifestation of extensive fungal infection in the single antimycotic (either PAF or AMB) 
treated animals and the lack of infection when PAF and AMB were used in combination. 
Furthermore, the lung injury score was lower in the combined treatment group (4±0.6, 
F(1,5)=4.96, P=0.08) than in the control group (6.3±0.8). However, the score of the PAF-
treated group (5±0.0) was almost identical to that of AMBtreated animals (5.3±0.6, 
F(1,4)=0.25, P=0.64). None of them was significantly lower than the control value (F(2,7)=1.11, 
P=0.38.) 
 
Combined treatment with a reduced concentration of AMB 
To investigate the efficacy of PAF, the previous experiment was repeated with a reduced 
concentration (2.5mg/kg) of AMB. The combined application of PAF and AMB (n=6) was 
compared with the single AMB-treated group (n=11). AMB alone delayed but did not prevent 
the death of the animals. After 8 days, all AMB-treated animals died, whereas its combined 
application with PAF not only delayed further the development of aspergillosis but also 
resulted in the survival of an infected mouse (16.6%). In contrast, all infected and untreated 
animals (n=12) died within 7 days. The combined PAF and AMB treatment extended the 
survival of the animals by 1 day, and one animal recovered from aspergillosis. Because the 
animals started to die earlier (at 2nd day) in the positive control group, the analysis of survival 
curves resulted in a slow (α=0.2822) Gompertz mortality rate. It was significantly higher in 
AMB (α=0.4292, P=0.002) treated groups, but the death of the animals started only at the 3rd 
day. In both cases the final number of animals (plateau) was 0. However, the combined 
treatment delayed the start of animal death to the 4th day, increased the survival of animals 
(plateau is 14.1%) and resulted in a significantly different mortality rate (α=0.4689, P=0.007) 
when compared with the untreated group. However, the log-rank test only showed significant 
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difference for the trend (P=0.03) and not between the survival curves themselves (P=0.09). 
There was no significant difference in the average survival time between the single treatment 
and positive control group (F(1,21)=1.79, P=0.20). However, the combined PAF and AMB 
treatment (F(1,16)=5.48, P=0.03) increased the lifetime of the animals significantly. 
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Discussion 
Aspergillus species have emerged as important causes of morbidity and mortality in 
immunocompromised patients. Despite the best treatment available, survival rate at 12 weeks 
is around 60–70% among patients with invasive pulmonary aspergillosis. Similar trend can be 
observed with dermatophytes which could spread when a big group of individuals regularly 
use communal changing rooms and swimming pools. Since the efficacy of the antifungal 
therapy is not complete in any type of fungal infections, the development and introduction of 
new antimycotic agents into human therapy would be beneficial beyond doubt. The 
Penicillium-derived antifungal protein (PAF) has been shown to be very effective in 
inhibiting the growth of several zoo-pathogenic fungi in vitro. The effects of PAF include 
hyperpolarization of themembranes of the fungal cells, aswell as an increase in reactive 
oxygen species that oxidize intracellular proteins, lipids, and nucleic acids, causing not only 
the disintegration of the cellular membranes but also that of the mitochondria. These effects 
were achieved at the concentration of 10 µg·ml−1 for the most sensitive species and were 
present at 50 µg·ml−1 for all affected molds. The concentrations used in these experiments 
were thus determined on the basis of these and our earlier experiments, where membrane 
hyperpolarization and obvious signs of apoptosis in Aspergillus hyphae or protoplasts were 
observed after treatment with PAF. In our study we, therefore, used PAF concentrations of 5–
2700 µg·kg−1 which corresponds to 2–1100 µg·ml−1. We thus expected that the highest 
concentration used in our study should be beyond the concentration that is sufficient to reach 
appreciable antifungal effects. This was indeed confirmed by testing the effects of lung 
homogenates of PAF treated mice on the growth of A. nidulans in vitro. In fact, two 
independent methods were used to establish the presence and antifungal efficiency of PAF in 
the lungs of PAF treated mice. First, mass spectroscopy experiments revealed that measurable 
amounts of the protein were present in the lungs of treated mice 4 h after the inhalation. 
Second, as mentioned above, the homogenate of these lungs successfully inhibited – by 
approximately 50–70% depending on the amount used – the growth of the A. nidulans, while 
lung homogenates from untreated mice had no such effects. These observations clearly 
demonstrated that not only was the protein still present in the lungs several hours after its 
introduction, but it retained its functional activity. It is also important to stress that mice 
treated with PAF showed no sign of any change in their behavior. They maintained regular 
activity as assessed by their normalwater and food intake as well as the amount of 
spontaneous exercise they did (distance and speed of running in a voluntary activity wheel. 
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Furthermore, they kept their body weight or even gained weight during the long term 
application of the protein. These are clearly in line with our earlier in vitro studies where we 
found no toxic effects of PAF on mammalian cells, on neurons, on endothelial cells, and on 
skeletal muscle fibers in particular. Taken together, our present observation with in vivo 
application of PAF clearly suggests that this antifungal drug – in the concentration range used 
– has no effect on the overall condition of the treated animals. Several organs, including the 
lungs, the liver, the kidneys, and mucosa of the nose taken from the animals that received the 
highest (2700 µg·kg−1) concentration of PAF, underwent histological examination. The fact 
that no morphological changes were observed in these organs clearly argues that PAF has no 
toxic effects, however for the overall toxicity study the nervous, musculoskeletal, 
cardiovascular, and lymphoreticular systems should be examined, too. Our observation, in 
case of the liver, the kidneys, and the skeletal muscles, is substantiated by the finding that 
liver enzymes, the concentration of the important ions, and creatine kinase levels, 
respectively, in the blood of PAF treated animals were essentially identical to those of control 
animals. It must be mentioned, on the other hand, that a small downward trend was observed 
in the plasma parameters when treated with PAF. Since for some parameters (creatinin, total 
bilirubin, and liver enzymes) is the increase, while for others (albumin, Ca, K, and Na) both 
deviations could be pathological, a systematic toxic effect of the protein was not observed. 
This again argues that PAF treatment does not induce any detectable toxic effect in mice. In 
earlier experiments the possible in vitro pro-inflammatory action of PAF was examined on 
human blood. In those studies blood samples were incubated with different concentrations of 
PAF and the levels of IL-6, IL-8 and TNF-α were measured. The rise in the production of 
cytokines was minimal as compared with the effect of LPS. Here we examined whether the in 
vivo application of PAF would alter total white blood cell count and the relative number of 
neutrophil granulocytes. Results clearly established that the presence of PAF neither induced 
any change in the number of white blood cells nor did it alter the relative amount of 
neutrophils. In addition there was no neutrophil infiltration in histological samples of all 
organs examined. Particularly for the lung, the injury score was similarly low in the control 
and PAF treated group showing that hemorrhage was absent in both group of animals. 
However since a foreign protein was administered to mice, the possibility of immune 
responses could not be excluded. These observations are in line with the data presented using 
the FDG-PET technique. Since 18FDG accumulation in tissues is proportional to cell 
metabolism, it is, therefore, a clear marker for tissue inflammation. It was also shown that 
PET could be useful for monitoring activation of macrophages as well as neutrophils in early 
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lung inflammation. One would thus expect a clear increase in 18FDG signal in tissues where 
inflammation occurred. Our MiniPET-II system has been shown to be sensitive enough to 
detect such signals. Nevertheless, the application of PAF did not result in an increase in 
18FDG related positron emission clearly indicating the lack of any inflammation of the lungs. 
On the other hand, LPS used as a positive control, initiated large increases in the SUV values 
similarly to those observed in LPS treated rats previously. It should be noted that in a few 
animals the lack or presence of inflammation as deduced from FDG-PET measurements was 
also confirmed by histological examinations substantiating our findings with 18FDG. 
Interestingly though SUV values were reduced in PAF treated animals as compared with their 
control counter mates. At the moment we do not have any clear explanation for this 
observation, nevertheless, similar results were obtained with some antineoplastic drugs in cell 
cultures. Earlier studies have demonstrated that PAF has inhibiting effects on several 
dermatophytes, which are a group of morphologically and physiologically related molds 
affecting the keratinous tissue of vertebrates. This raises the possibility that PAF could have a 
potential therapeutic use in dermatophytosis. Such application would inevitably require that 
local application of PAF on the skin and should not evoke any local inflammatory response. 
Measuring the changes of ear thickness following the surface application of different drugs 
has been an acceptedmodel for detecting any inflammation in the skin. Our results from these 
experiments prove that PAF does not induce any inflammation if applied locally on the skin. 
This, therefore, raises the possibility that the protein could also be a potential candidate for the 
treatment of topical and systemic dermatophytosis. Taken together these results proved a good 
tolerance – no toxicity, no inflammation inducing effect – of PAF in several organs of mice, 
providing a basis for experiments evaluating the efficacy of PAF as a promising antifungal 
therapy. 
We compared the in vivo antifungal activity of PAF when administered either intranasally or 
IP alone or in combination with amphotericin B — as an in vitro interaction study confirmed 
that the effect of these drugs is synergistic against A. fumigatus — in an 
immunocompromised mouse model of invasive pulmonary aspergillosis initiated by A. 
fumigatus. The model was highly reproducible, and all untreated animals died within 9 days 
following the fungal infection. Although PAF is a protein, it is highly stable, and, hence, it is 
easy and safe to prepare it for administration independent of the mode of application. In the 
case of nasal application, a concentration high enough to have antifungal activity in vitro was 
determined in the lungs. However, independent of the mode of application, the protein was 
undetectable in serum. Notably, accumulation of PAF over time was not observed, which was 
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most likely the consequence of its short half-life within the body. It should be noted that blood 
samples were taken 120 min after the last intraperitoneal administration of the drug and that 
PAF is small enough to be filtered by the glomeruli and thus excreted by the kidneys. On the 
basis of this, to achieve detectable concentrations of PAF in the serum of mice, the protein 
should be administered in doses higher than those used in our experiments. There may be a 
threshold therapeutic concentration for the successful medication of IPA, which should be 
determined in future studies. The intraperitoneal administration of PAF was beginning to 
prevent the spread of fungi in the lungs around days 5 and 6 post-infection, but finally it was 
not able to overcome the fungal invasion. It is remarkable that PAF alone was almost as 
effective as the lower (2.5 mg/kg) concentration AMB, an antimycotic used frequently in the 
medication of IPA. Furthermore, the combined application of PAF and AMB was clearly 
superior to either single antimycotic (PAF or AMB) treatment when increased survival times 
were considered. The dose of AMB (5mg/kg) used in this model was not able to prevent the 
progression of IPA in mice. In human treatment, AMB is usually administered in intravenous 
(iv.) infusion for 1–2 weeks, and its typical dosage is 3 mg/kg·day. With higher dosage of 
AMB (10 mg/kg·day), the incidence of nephrotoxicity increases. However, in patients with 
IPA, no difference was observed in efficacy between the low and high dosage of AMB 
showing ~ 50% positive effect. A comparative study with posaconazole and AMB found that 
although the survival with posaconazole was 70–90%, it was only 0–50% with AMB. The 
efficiency of AMB and anidulafungin was also compared, and both antimycotics could 
prolong survival, but finally at least 90% of the animals died in every group. These findings 
are in good accordance with our observations. We have to note notwithstanding that the 
intraperitoneal administration of AMB is less clinically relevant, but its synergic effects with 
PAF could also be investigated in our animal model. It was shown previously that the 
distribution of AMB in the lungs is significantly different when administered IP versus 
intravenously. As IP administration resulted in a higher level of AMB in the lungs than the iv. 
route, in further animal studies the applied concentration should be different than was used 
here. It is also possible that the histological changes we observed were partly the consequence 
of the accumulation of AMB, although we used AMB at a low concentration and only three 
times. It is also promising that the combined application of PAF with lowered AMB (2.5 
mg/kg) was as effective or even better than the combined treatment with the high 
concentration AMB. This finding raises the possibility of combined treatment with reduced 
AMB and thus decreased toxicity, which has been observed in mice suffering from IPA. In 
contrast, no toxicities or side effects of PAF have been reported thus far. Similar to other 
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pathogenic fungi, Aspergillus spp. can develop resistance against different antifungal agents. 
For example, itraconazole resistance was first reported in 1997, and more than 50% of the 
strains resistant to itraconazole were cross-resistant to other azoles, such as voriconazole and 
posaconazole, which are primary drugs in antifungal therapies. Resistance to antimycotics can 
emerge through different mechanisms, such as increased drug reflux, modification or over-
expression of target enzymes, up-regulation of homeostatic stress-response pathways, 
exogenous cholesterol import or altered drug uptake. Owing to the emergence and spread of 
resistance towards frequently used antifungals, there is an urgent need for new types of 
antimycotics effective against human opportunistic Aspergillus spp. Our study demonstrated 
for the first time that PAF has potential in vivo against IPA even when administered at 
relatively low concentrations. Furthermore, the fact that AMB interacted synergistically with 
PAF in vitro indicated that such combinations may also have good efficacy in the treatment of 
neutropenic patients suffering from IPA. Future in vivo studies should aim at shedding light 
on further interactions of antimycotic drugs with PAF and determining the threshold 
concentrations at which IPA could be blocked or even reversed. 
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Summary 
The antifungal protein of Penicillium chrysogenum (PAF) inhibits the growth of important 
pathogenic filamentous fungi, including members of the Aspergillus family and some 
dermatophytes. PAF was proven to have no toxic effects on mammalian cells in vitro. To 
prove that PAF could be safely used in therapy, experiments were carried out to investigate its 
in vivo effects. Adult mice were inoculated with PAF intranasally in different concentrations, 
up to 2700 µg/kg daily, for 2 weeks. Even at the highest concentration -a concentration highly 
toxic in vitro for all affected molds used- animals neither died due to the treatment nor were 
any side effects observed. Histological examinations did not find pathological reactions in the 
liver, in the kidney, and in the lungs. Mass spectrometry confirmed that a measurable amount 
of PAF was accumulated in the lungs after the treatment. Lung tissue extracts from PAF 
treated mice exerted significant antifungal activity. Small-animal positron emission 
tomography revealed that neither the application of physiological saline nor that of PAF 
induced any inflammation while the positive control lipopolysaccharide did. The effect of the 
drug on the skin was examined in an irritative dermatitis model where the change in the 
thickness of the ears following PAF application was found to be the same as in control. Since 
no toxic effects of PAF were found in intranasal application, the next step was to test its 
efficacy against invasive pulmonary aspergillosis (IPA), experiments were carried out in mice 
suffering from IPA. Adult mice were immunosuppressed and then infected with Aspergillus 
fumigatus. After stable infection, the animals were inoculated with PAF intranasally at a 
concentration of 2.7 mg/kg twice per day. At this concentration -which is highly toxic in vitro 
to A. fumigatus- the mortality of the animals was slightly delayed but finally all animals died. 
Histological examinations revealed massive fungal infections in the lungs of both PAF-treated 
and untreated animal groups. Because intranasally administered PAF was unable to overcome 
IPA, modified and combined therapies were introduced. The intraperitoneal application of 
PAF in animals with IPA prolonged the survival of the animals only 1 day. Similar results 
were obtained with amphotericin B (AMB), with PAF and AMB being equally effective. 
Combined therapy with AMB and PAF -which are synergistic in vitro- was found to be more 
effective than either AMB or PAF treatment alone. As no toxic effects of PAF in mammals 
have been described thus far, and, moreover, there are so far no A. fumigatus strains with 
reported inherent or acquired PAF resistance, it is worth carrying out further studies to 
introduce PAF as a potential antifungal drug in human therapy. 
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